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In the first part of this overview, we described the life cycle of 
the influenza virus and the pharmacological action of the cur-
rently available drugs. This second part provides an overview of 
the molecular mechanisms and targets of still-experimental drugs 
for the treatment and management of influenza. 
Briefly, we can distinguish between compounds with anti-influ-
enza activity that target influenza virus proteins or genes, and 
molecules that target host components that are essential for viral 
replication and propagation. These latter compounds have been 
developed quite recently. Among the first group, we will focus 
especially on hemagglutinin, M2 channel and neuraminidase 
inhibitors. The second group of compounds may pave the way for 
personalized treatment and influenza management. Combination 
therapies are also discussed.
In recent decades, few antiviral molecules against influenza virus 
infections have been available; this has conditioned their use dur-
ing human and animal outbreaks. Indeed, during seasonal and pan-
demic outbreaks, antiviral drugs have usually been administered in 
mono-therapy and, sometimes, in an uncontrolled manner to farm 
animals. This has led to the emergence of viral strains displaying 
resistance, especially to compounds of the amantadane family. For 
this reason, it is particularly important to develop new antiviral 
drugs against influenza viruses. Indeed, although vaccination is the 
most powerful means of mitigating the effects of influenza epidem-
ics, antiviral drugs can be very useful, particularly in delaying the 
spread of new pandemic viruses, thereby enabling manufacturers 
to prepare large quantities of pandemic vaccine. In addition, anti-
viral drugs are particularly valuable in complicated cases of influ-
enza, especially in hospitalized patients.
To write this overview, we mined various databases, including 
Embase, PubChem, DrugBank and Chemical Abstracts Service, 
and patent repositories.
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Summary
In the first part of this overview [1], we described the 
life cycle of the influenza virus and the pharmacological 
action of the currently available drugs. In this second 
part, we will overview the molecular mechanisms and 
the targets of still-experimental drugs for the treatment 
and management of influenza. Figure 1 shows the attack 
points of several potential antiviral drugs.
Antiviral drug research is a particularly active field and 
new approaches have been developed. Briefly, we can 
distinguish between compounds with anti-influenza 
activity that directly target influenza virus proteins or 
genes, and molecules that target host components that 
are essential to viral replication and propagation. Among 
the former group, we will focus especially on hemag-
glutinin (HA), Matrix protein 2 (M2) and neuramini-
dase (NA) inhibitors (HAIs, NAIs). The latter molecules 
have been implemented quite recently and may pave the 
way for personalized treatment and management of in-
fluenza. Moreover, it is expected that the inhibition of 
host factors (such as single molecules) and/or complex 
mechanisms (such as intracellular signaling cascades 
and pathways) may act against different influenza virus 
strains and may be less prone to the emergence of drug 
resistance than the inhibition of viral components [2, 3]. 
Therapies that combine two or more compounds belong-
ing to the same group or different groups are also dis-
cussed.
To write this overview, we mined various chemical da-
tabases, including Embase [4], PubChem [5, 6], Drug-
Bank  [7] and Chemical Abstracts Service (CAS)  [8], 
as well as patent repositories and clinical trials regis-
tries [9]. We also scanned extant reviews and consulted 
the gray literature (books, proceedings, conference ab-
stracts, posters and congress communications) in order 
to increase coverage of the anti-influenza drugs included 
in the present article. With regard to the search strategy, 
we used a mining approach similar to that described in 
Eyer and Hruska [10]. No time or language filters were 
applied.
To the best of our knowledge, this article constitutes the 
most comprehensive and up-to-date overview of anti-
influenza compounds in the literature. It can be used 
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also as a working bibliography and a mapping review 
for scholars doing research in the field.
Along with this paper, a database is currently being de-
signed and developed and will be accessible at the CIRI-
IT institutional website [11]. 
Entry and Attachment Inhibitors 
Effective antiviral compounds that interfere with the at-
tachment and entry of the influenza virus into the host 
cell include triterpenoids [12] such as glycyrrhizic acid 
(GA)  [13], glycyrrhizin (GR)  [14], glycyrrhetinic ac-
id  [15] and further derivatives extracted from licorice 
and present in some Chinese medicaments. GR is the 
most active of these molecules and can repress the rep-
lication of H3N2 and H5N1, as well as of several virus-
es [16]. It can be delivered as an approved parenteral GR 
preparation (Stronger Neo-Minophafen C, SNMC), and 
glutamyl-tryptophan can be added in order to increase its 
activity [17, 18]. GR is able to inhibit entry of the virus 
into the host cell, and reduces the level of pro-inflamma-
tory molecules such as chemokine (C-X-C motif) ligand 
type 10 (CXCL10), interleukin 6 (IL6), CC chemokine 
ligand type 2 (CCL2), and CC chemokine ligand type 5 
(CCL5) [19, 20]. It also exerts an anti-apoptotic action. 
In addition, GR hinders monocyte recruitment and has 
anti-oxidant activities, inhibiting the formation of influ-
enza virus-induced reactive oxygen species (ROS) [21]. 
It extensively modulates gene expression, activating in-
terferon-gamma (IFN-gamma) and reducing the expres-
sion of Nuclear factor kappa B (NFκB), c-Jun N-termi-
nal kinase (JNK), and p38. Furthermore, GR reduces 
high-mobility-group box type 1 (HMGB1) [22]. Prom-
ising glycyrrhizin derivatives include spacer-linked 
1-thioglucuronide analogues [23]. GA inhibits influenza 
virus growth and replication in embryonated eggs [24]. 
Moreover, it can be used as an adjuvant in the prepara-
tion of anti-influenza vaccines [25].
Other triterpenoids  [26], such as the saponins and 
uralsaponins M-Y from the roots of Glycyrrhiza ura-
Fig. 1. The attack points of several antiviral drugs are shown, with a particular focus on future potential compounds and strategies against 
influenza virus. Abbreviations: hA: hemagglutinin; m: matrix protein; m1: matrix type 1 protein; m2: matrix type 2 protein; mTOC: microtu-
bule-organizing center; NA: neuraminidase; NAIs: neuraminidase inhibitors; Nep: nuclear export protein; res: recycling endosomes; rNA: 
ribonucleic acid; rNp: ribonucleoprotein; sirNA: short interfering rNA; TBhQ: Tert-butyl-hydroquinone. 
virion release by m2 and NA. 
This phase can be inhibited 
by NAIs.
viral budding by hA, NA, m1 and m2 
proteins. This phase can be inhibited by 
Amantadine, rimantadine or derivatives, 
or possibly by Omeprazole, Chloroquine 
and TBhQ.
virion entry 
by hA, this phase 
could be inhibited by 
Arbidol.
entry in cytosol by m2 and hA fusion 
peptide, this phase can be inhibited 
by Amantadine, rimantadine or 
derivatives, or possibly Omeprazole, 
Chloroquine, TBhQ, and human 
defensin 3, among others.
Trafficking in cytoplasm by a 
diffusion mechanism, without 
microtubules, intermediate 
filaments and actin.
entry in the nucleus 
by importins and 
polymerases.
viral protein synthesis by 
polymerases, this phase can 
be inhibited by ribavirin 
or, possibily, by sirNAs and 
oxibutanoic acid derivatives.
rNA replication by polymerases, 
ribavirin can interfere with this 
replication phase, and possibly also 
Clarithromycin, Nitric oxide and 
T-305, among others, could be 
useful.
exit from the nucleus by Nep and 
apoptosis. drugs against apoptosis 
could be used to interfere with this 
phase of viral replication.
rNps trafficking by mTOC 
and res.
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lensis  [27], exhibit anti-influenza and anti-HIV activi-
ties. Moreover, saponins can be used as vaccine adju-
vants [28-31] and modulate the expression of cytokines 
and chemokines  [32, 33]. Further triterpenoid deriva-
tives share broad antiviral actions [34-38].
Dextran sulphate (DS) is a negatively charged sulphat-
ed polysaccharide. Besides inhibiting virus entry and 
attachment, it represses HA-dependent fusion activ-
ity  [39-41] and NA-dependent activity  [42]. However, 
mutations conferring resistance to DS are described in 
the literature [43]. Oxidized dextran can be administered 
as a prevention [44-46].
Other sulphated molecules include the sulphated syalil 
lipid NMS03, which is effective against IAV, Human 
Metapneumovirus (HMPV) and picoRNAvirus. It is as-
sumed that it interferes with fusion, but the precise na-
ture of its mechanism is still unknown [47].
Another potential fusion inhibitor is BTA9881, which 
has shown promising activity against RSV [48, 49].
Lysosomotropic agents, such as concanamycin A [50-53], 
the macrolide antibiotic bafilomycin A1 [54, 55], saliphe-
nylhalamide [56], N,N’-Dicyclohexylcarbodiimide [52], 
and chloroquine  [57-64], inhibit vacuolar ATPase (V-
ATPase) and reduce endosome acidification and lyso-
some number. They act on the CME pathway, but are 
unable to block clathrin caveolae-independent endocy-
tosis. It should be stressed that the anti-influenzal ac-
tivity of these compounds strongly depends on the pH 
of the cellular environment and that some scholars have 
reported conflicting findings about their in vivo effec-
tiveness [65]. 
Extract from milk thistle seeds, known as silymarin, a 
complex mixture of flavonolignans, and its main com-
ponent silibinin are active against influenza [66]. Also 
silybin and its derivative can block virus entry and 
regulate autophagy, repressing the formation of oxida-
tive stress species and triggering activation of the ex-
tracellular signal-regulated kinase (ERK)/p38 mitogen-
activated protein kinase (MAPK) and IκB kinase (IKK) 
cascades [67]. Other silybin derivatives include silybin 
fatty acid conjugates, which have strong anti-oxidant 
properties [68].
Compounds from Melaleuca alternifolia (tea tree) oil 
(TTO) concentrate (MAC)  [69, 70] have a broad anti-
microbial activity. In silico simulations have shown that 
these compounds can interfere with virus entry and fu-
sion of the influenza virus [71, 72].
Other potential compounds include Amaryllidaceae 
alkaloids from Lycoris radiate, such as lycorine, hip-
peastrine, hemanthamine and 11-hydroxy vittatine, 
which can also inhibit the nuclear-to-cytoplasmic export 
of the ribonucleoprotein (RNP) complex [73].
Curcumin is able to inhibit virus entry and HA [74]. It 
also has antioxidant, anti-inflammatory, anticancer, an-
tiviral, antibacterial and antidiabetic properties, among 
others  [75]. Curcumin acts against a large array of 
targets  [76]. Curcumin is also active against other vi-
ruses  [75, 77]. Rajput and collaborators showed that 
animals on a diet enriched in curcumin displayed an im-
proved immune response  [78]. Surprisingly, curcumin 
derivatives do not exhibit anti-influenza activity [79].
LADANIA067, extracted from the leaves of the wild 
blackcurrant (Ribes nigrum folium) [80, 81], has shown 
antiviral activities both in vivo and in vitro, without hav-
ing any effect on influenza virus metabolism or growth/
proliferation.
Fattiviracin A1 is a recently discovered antiviral  [82]. 
Besides inhibiting both IAV and IBV, it is active against 
HIV, HSV and VZV [83].
Lignans exert a good anti-influenza activity [84, 85] Ger-
macrone is a molecule purified from Rhizoma curcuma. 
It can be effectively combined with oseltamivir [86]. 
Akt inhibitors are also effective entry inhibitors. These 
include peptide “Akt in”, which may be TCL1- or 
TCL1b-based, MK2206 [87, 88] and Ma-xing-shi-gan-
tang (MXSGT), a traditional Chinese herbal decoc-
tion  [89]. Everolimus, an inhibitor of the PI3K-Akt-
mTOR pathway, is also a valuable tool against influ-
enza [90].
Among anti-attachment drugs, Fludase (DAS181) 
has potential anti-influenza virus properties [91-103]. 
This medication, which has proved capable of inhibit-
ing human and avian influenza viruses in pre-clinical 
studies, acts by mimicking NA and destroying the 
molecules of sialic acid receptors on the host cell sur-
face. It is also effective against NA-resistant influenza 
strains [92, 93, 103]. 
HA Inhibitors
An effective class of HAIs is that of the amide deriva-
tives [104-107].
Gossypol is a natural phenolic aldehyde extracted from 
the cotton plant and blocks the dehydrogenase family 
enzymes  [108, 109]. Its antiviral properties emerged 
during a 1970 study, in which an experimental model 
of influenza pneumonia was used  [108]. In particu-
lar, chiral (+)-gossypol is more active than (–)-gossy-
pol [110, 111]. 
Another antiviral against HA is Entry Block-peptide 
(EB-peptide), a peptide derived from fibroblast growth 
factor 4 (FGF4) [112]. EB-peptide can inhibit virus entry 
and attachment, being effective even when administered 
post-infection. Besides repressing influenza viruses, EB-
peptide is also active against other viruses [113]. It can 
also be used as an adjuvant in the formalin-inactivated 
influenza whole-virus vaccine, triggering phagocytosis 
of influenza virions. Other peptides similar to EB-pep-
tide are the FluPep (FP) peptides, such as FP1 (Tkip) 
and FP2-FP9 [114]. Tkip was designed as a mimetic of 
the suppressor of the cytokine signaling (SOCS) protein, 
which is involved in mediating the immune response to 
influenza. Furthermore, peptide NDFRSKT has strong 
antiviral properties, but with unknown therapeutic char-
acteristics [115, 116]. 
Other molecules which bind to HA are collectins 
(CLs)  [117]. Human CLs and bovine conglutinin, CL-
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43 and CL-46 confer protection against influenza infec-
tion [118-122]. 
A related group of molecules is the ficolins (such as 
H-ficolin and L-ficolin), present at high concentra-
tions in serum and in bronchoalveolar secretions [123]. 
They bind not only to HA but also to NA in vitro mod-
els  [124]. These proteins can be engineered in such a 
way as to become more active against influenza virus; 
for example, Chang and collaborators designed recom-
binant chimeric lectins consisting of mannose-binding 
lectin (MBL) and L-ficolin [125]. However, because of 
their role in the inflammatory response, their potential 
use in humans requires more complete analysis. Re-
cently, agglutinins such as NICTABA, UDA [126] and 
protectins like protectin D1 [127-130] have been found 
to have anti-influenza propriety [131].
An interesting compound, which binds to specific 
high-mannose oligosaccharides of HA is Cyanovirin-N 
(CVN) [132]. In 2003, O’Keefe et al. demonstrated its 
potent in vitro antiviral activity against a wide range of 
IAVs and IBVs, including NA-resistant strains, though 
resistance induced by mutations that affect the glycosila-
tion site of HA seems to arise quite naturally [133]. 
Clarithromycin (CAM), able to inhibit influenza virus 
replication in vitro and in cell cultures, appears to have 
3 mechanisms of action against type A seasonal Influ-
enza virus. It was recently showed that CAM reduces 
the expression of human influenza virus receptors on the 
mucosal surface of the airways, reduces the production 
of nuclear factor-kB (NF-kB), and increases pH inside 
the endosomes [134, 135].
Norakin (Triperiden) is an anticholinergic drug that 
interacts with HA [136, 137]. This interaction may be 
indirect, being mediated by an increase in the inter-
nal pH in the pre-lysosomal compartment  [138-140]. 
However, strains resistant to Norakin have been de-
scribed [141-144]. Also Norakin derivatives seem to be 
effective antiviral compounds [145].
Another interesting compound is nitazoxanide [146-151], 
useful for the treatment of protozoal and bacterial infec-
tions and is active against hepatitis and influenza viruses 
or rotaviruses. Further thiazolides act at the post-trans-
lational level by selectively blocking the maturation of 
viral HA at a stage preceding that of resistance to en-
doglycosidase H digestion, thus interfering with HA in-
tracellular trafficking and insertion into the host plasma 
membrane, which is a key step in the correct assembly 
and exit of the virus from the host cell. 
Bacillus intermedius ribonuclease (BINASE) shows a 
good anti-influenza activity. BINASE and HA interact 
with sialic acid on the cell surface and penetrate into 
the host cell. Subsequently, viral RNA is released and 
cleaved by BINASE [152, 153]. 
High mannose-binding lectins (HMBL) are powerful in-
fluenza and HIV inhibitors [154].
Rutin, quercetin, and related compounds, extracted from 
elderberry fruit (Sambucus nigra L.) [155-161] are other 
HA inhibitors. Xylopine and rosmaricin have an amine 
group that interacts with HA [162, 163].
Theaflavins (TFs) from black tea have a strong anti-in-
fluenza activity, inhibiting HA and reducing the level of 
IL6, thus exerting an anti-inflammatory and anti-apop-
totic action [164-166].
M2 Inhibitors
M2 inhibitors can be basically divided into 2 groups. 
The first includes compounds derived from the leads of 
amantadine and rimantadine and its hydroxylated deriv-
atives [167-172]. The second includes non-adamantane 
derivatives, which are promising drugs against influenza 
viruses [173]. Some of these compounds have been spe-
cifically designed for some important mutants of the M2 
ion channel of IAV [174-177].
Regarding molecules putatively capable of blocking the 
ion pump, Gasparini and coworkers recently conducted 
a field investigation into the effect of omeprazole family 
compounds (OFC) [178] on Influenza-like Illness (ILIs). 
The results showed that subjects treated with omeprazole 
family compounds displayed a lower risk of catching ILI 
(ORadj = 0.29, 95% CI: 0.15-0.52) than non-treated sub-
jects. Molecular docking and molecular dynamics (MD) 
simulations, which are a common method of searching 
for new potential drugs, seem to confirm these find-
ings [179]. The M2 Protein – Protein Data Bank (PDB) 
code 3C9J [180] – was simulated as being embedded in 
a dipalmitoylphosphatidylcholine (DPPC) membrane in 
complex, with its ligands amantadine and rimantadine 
being used as positive controls and omeprazole as a pu-
tative ligand. The thermodynamic integration method 
was used in order to estimate binding free energies of 
the ligands. Free-energy calculations imply omeprazole 
as a potent anti-viral drug. Also another study has sug-
gested the antiviral properties of omeprazole against Eb-
olavirus [181].
Polyamines such as spermine [182, 183], spermidine and 
putrescine have recently been identified as intrinsic rec-
tifiers of potassium channels. Indeed, the M2 protein has 
a binding site for polyamines, which is different from 
the amantadine binding site  [184]. Polyamines have 
quite recently been exploited in designing anti-influenza 
vaccines [185, 186].
Spiropiperidine M2 inhibitor and its derivatives appear 
promising in acting against amantadine-resistant virus-
es; in particular, spiropiperidine-9 seems to be the most 
active [187]. 
Among natural products, pinanamine derivatives [188] 
and 24-E-ferulate [188] have a good influenza activity.
Endosomal and lysosomal inhibitors
Substituted salicylanilides appear promising antivi-
ral agents  [190-193]. In particular, Niclosamide  [192], 
which is approved for human use against helminthic in-
fections, besides being active against influenza viruses, 
has also shown anti-neoplastic and broad antiviral ef-
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fects, being active against SARS-related coronavirus 
and Human Rhinovirus (HRV). 
Lysosomotropic agents [50-64] have also been already 
discussed. Further compounds include molecules ob-
tained from TTO [69-72], which have already been men-
tioned. 
Protease inhibitors 
The cleavage of HA can be blocked not only by anti-
M2 protein compounds, but also by inhibition of the 
necessary proteases  [194]. Given the great importance 
of the proteases in the viral replication cycle, many au-
thors [195, 196] have directed their research towards an-
ti-protease medications that could block, or at least miti-
gate, the consequences of HA cleavage. HA can also be 
blocked by natural products such as Hepatocyte growth 
factor activator inhibitor 2 (HAI-2)  [197]. Several an-
ti-protease drugs have been studied in in vitro models, 
animals and humans, such as Camostat mesilate [198], 
epsilon-aminocapronic acid  [199], leupeptin  [200] and 
Aprotinin  [201], which has been approved for topical 
use in a small-particle aerosol formulation in Russia. A 
theoretical advantage of antiviral activity against enzy-
matic activities of the host is that these molecules would 
not lead to the selection of resistant viral variants.
Other molecules can interfere with the mechanism of 
fusion of the endosomal and viral membranes [202]. In-
deed, numerous small molecules that block virus infec-
tivity by inhibiting the conformational changes required 
for HA-mediated membrane fusion have been identified. 
Russell et al. [194] have demonstrated that TBHQ (Tert-
butyl-hydroquinone) stabilizes the neutral pH structure 
and, in this way, presumably, inhibits the conformation-
al rearrangements required for membrane fusion. Fur-
thermore, Leikina et al.  [203] have demonstrated that 
human β-defensin 3, a lectin, can inhibit HA-mediated 
influenza viral fusion.
Regarding the compounds targeted against the transcrip-
tion and replication of vRNA, one of the first drugs 
developed is Ribavirin (RIB). RIB, also known by the 
trade name “Virazole”, is a nucleoside analog [204]. Its 
mechanism of action is not completely known. Howev-
er, Inosine 5’-monoposphate dehydrogenase (IMPDH) 
appears to be the principal target of the molecule. This 
inhibition diminishes the intracellular concentration of 
GTP (Guanosine-5’-triphosphate), and this is thought to 
stop viral protein synthesis and limit vRNA replication. 
Crotty et al. also demonstrated that RIB is a lethal vR-
NA mutagen [205]. However, the need for high doses of 
the drug in order to have obtain good clinical results has 
limited the use of RIB as an anti-influenza drug, and a 
recent revision of the literature by Chan-Tack et al. sug-
gests that there are no conclusive results on the benefi-
cial use of Virazole for the treatment of influenza [206]. 
RIB can also be delivered as a liposome encapsulated 
with muramyl tripeptide (MTP-PE) [207].
α(1)-antitrypsin (AAT) [208] is a serine protease inhibi-
tor of elastase and proteinase-3 (PR-3). This protein is 
produced by the liver and its expression increases par-
ticularly during the acute-phase response. It also has 
immunomodulatory, anti-inflammatory and tissue-pro-
tective properties, reducing influenza-related complica-
tions and morbidities. As an immunomodulator, AAT 
mediates the maturation and differentiation of dendritic 
cells (DCs) and T regulatory cells (Tregs), activating the 
IL1 receptor antagonist (IL1RA) and inducing IL10 re-
lease. Moreover, it exerts an anti-apoptotic effect, inhib-
iting caspases-1 and -3. The role of AAT in inhibiting 
influenza viruses is consistent with the clinical obser-
vations that subjects with AAT deficiency are exposed 
to the risk of severe influenza-related complications and 
should therefore be vaccinated [209, 210]. 
Stachyflin, acetylstachyflin and its phosphate esther or 
oxo derivatives [211, 212] exert their inhibitory activity 
on a variety of HA subtypes of IAV (H1, H2, H5 and 
H6, among others) but have no activity on H3 subtype 
IAV or on IBV [213-217]. The metabolites of stachyflin 
and its derivatives include compounds such as cis-fused 
decalin  [214]. Stachyflin compounds can be delivered 
intranasally or orally, using PEG 400 as vehicle [211]. 
However, some amino acid substitutions confer resist-
ance to stachyflin [212].
BMY-27709, a salicylamide derivative, and its ana-
logues are other useful compounds [218, 219]. 
Thiobenzamide derivatives have a good activity profile. 
In particular, the axial disposition of the thioamide moiety 
has proved to be crucial to inhibitory activity [220].
Ulinastatin [221] is a protease inhibitor, which also pro-
tects lysosome integrity. Its use has been suggested for the 
treatment of avian influenza [221] and severe influenza-
related complications, such as encephalopathy [222] and 
acute respiratory distress syndrome (ARDS)  [223, 224]. 
Indeed, a recently published meta-analysis has shown 
that this drug is effective in managing acute lung injury 
(ALI) and ARDS [225].
The ubiquitin-specific peptidase type 18 (USP18) 
protease inhibitor ISG15 is another promising mole-
cule [226]. ISG15 is part of the interferon-regulated cel-
lular cascade. USP18 was found to be one of seven genes 
which predict a response to influenza virus [227]. This 
finding was reproduced by Liu and collaborators [228].
Polymerase inhibitors
Other antiviral strategies have been directed against the 
viral RNA polymerase  [229, 230]. The trimeric poly-
merase complex has multiple enzymatic activities and 
can thus be targeted at different sites of action. For in-
stance, nucleoside/nucleotide compounds have been de-
veloped against other viruses, namely HIV, HBV, etc.
A historical compound is moroxydine  [231-233]. It is 
also active against HSV and VZV.
The most thoroughly studied of these molecules is Favi-
piravir (T-705). In vitro studies have demonstrated the 
high antiviral potency of the drug and mouse studies 
have demonstrated its protective efficacy against a wide 
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range of influenza viruses A and B. This molecule also 
seems to be effective against other viruses [234-238].
More recently, other compounds directed towards anti-
nucleasic activities have been studied, such as the series 
of hydroxypyridinone, which appears to have antiviral 
activity in cells [230]. 
On studying 33 different kinds of phytochemicals, other 
scholars have identified a family of drugs called march-
antines, which appear to interact with the PA subunit of 
the endonuclease [239].
An attractive strategy for developing anti-polymerase 
compounds appears to be that of interfering with the sub-
unit binding interfaces of PB1 and PA, which are very 
well conserved in different Influenza virus strains [240]. 
Thus, these compounds would reduce the transcriptional 
activity of the viral RNA polymerase. One such promis-
ing compound is AL18, which is also active against hu-
man cytomegalovirus [241]. 
Furthermore, the recent definition of the PB1/PB2 bind-
ing interface by means of crystallography  [242] has 
prompted researchers to study synthetic peptides, such 
as peptide 1-37 and peptide 731-757, which seem to in-
hibit the interaction between PB1 and PB2 [243-247].
Azaindole VX-787, an inhibitor of PB2 [248-251], is 
able to interfere with the cap-snatching activity of the 
polymerase complex of the influenza virus. The small 
GTPase Rac1 inhibitor NSC23766 exhibits a similar ac-
tivity profile [252]. 
Nuclear pathway inhibitors
Leptomycin B (LMB) inhibits nuclear export signal 
(NES)-mediated vRNP export, as well as NES-receptor 
CRM1/exportin-1 (XPO-1); however, it is somewhat 
toxic [253]. 
Verdinexor (KPT-335) [254] is a new-generation XPO-
1 antagonist that is well tolerated in animal models and 
seems to be effective against both IAV and IBV. It is a 
selective inhibitor of nuclear export (SINE). 
NP inhibitors
Given the fundamental importance of the NP in modu-
lating the replication cycle of the virus, many authors 
have investigated strategies for preventing its produc-
tion. Moreover, molecules that prevent the functional 
polymerization of the NP monomers have also been 
studied, such as, for example, Nucleozin (NCZ) [255]. 
It also blocks viral RNA and protein synthesis and tar-
gets vRNP nuclear export and its cytoplasmatic traffick-
ing. As a final result, fewer and smaller influenza viral 
particles are released. NCZ derivatives include a quite 
effective compound, namely 3061 (FA-2), which has 
been shown to inhibit the replication of the influenza A/
WSN/33 (H1N1) virus, though NP-mutant strains have 
displayed resistance to this drug [256].
Jiang and collaborators screened a peptide library and 
discovered that the NP-binding proline-rich peptide was 
particularly effective against influenza viruses [257].
Another interesting molecule is the interferon-inducible 
Mx1 protein [258, 259].
Cycloheximide (CHX), which is also active against en-
terovirus-71 (EV-71), coxsackievirus B, and actinomy-
cin D, are quite effective chemicals [260-262].
Intriguingly, clinically licensed anti-cyclooxygenase-2 
(COX-2) Naproxen also appears to inhibit the functional 
polymerization of NP monomers. Its derivatives, such as 
naproxen A and C0, also appear quite promising [263].
Another drug directed against the NP is Ingavirin, which 
has been licensed in Russia. Indeed, Ingavirin interacts 
with the transport of newly synthesized NPs from the 
cytoplasm to the nucleus  [264-272]. It is also active 
against parainfluenza virus, adenoviruses and human 
metapneumovirus [273]. 
NA inhibitors
NAIs include peramivir and lanimamivir deriva-
tives [274-289].
Baicalin induces autophagy and acts against both 
NA [290] and NS1 [291-293]. 
Isoscutellarein is another compound that inhibits influ-
enza virus sialidase. Its derivative is also active against 
influenza [294, 295].
NS1 inhibitors
Another potential strategy against influenza is to block 
the NS1 protein, a non-structural protein that is very 
important during the viral replication cycle. Indeed, the 
NS1 protein down-regulates the cellular production of 
IFN α/β. Furthermore, it has been demonstrated that 
NS1 also modulates other crucial aspects of influenza vi-
rus replication, namely viral RNA replication, viral pro-
tein synthesis, and general host-cell physiology [1, 296]. 
Finally, NS1 probably has an anti-apoptotic function in 
the early phases of replication. The meaning of apopto-
sis during influenza A virus replication is ambiguous, 
although it is usually considered to be a cellular antiviral 
defense that limits virus replication. Therefore, influen-
za viruses have acquired different ways of procrastinat-
ing this seeming host strategy [1]. Nonetheless, cellular 
pro-apoptotic factors favor the effective replication of 
influenza viruses, and some viral proteins, such as NA 
and PB1-F2, carry out pro-apoptotic tasks [1, 297]. Fur-
thermore, some compounds that act against the NS1 pro-
tein have been studied. In this perspective, peptide-me-
diated inhibition of NS1 – CPSF30 has been proposed 
as a strategy for mitigating viral replication [298, 299]. 
Unfortunately, this virus-specific approach leads to viral 
mutation and the occurrence of drug resistance. 
More recently, Jablonski et al. studied a class of mol-
ecules derived from the NSC125044 compound, which 
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displayed NS1 protein inhibition in viral replication as-
says [300].
Regulated in development and DNA damage respons-
es-1 (REDD1) is a molecule that has recently emerged 
from comprehensive biochemical screening. Moreover, 
REDD1 inhibits the mTOR pathway [301].
Other RNA synthesis inhibitors
Cordycepins extracted from Cordyceps, a genus of as-
comycete fungi, are used for diverse medicinal purposes 
because of their different pharmacological actions with 
hypothetical anti-viral activity [302].
Caspase inhibitors
Apoptosis plays a major role in the influenza virus life 
cycle [303-307]. Indeed, in order to replicate, the virus 
activates the mechanism of apoptosis through the ac-
tivation of caspase  3. Cellular inhibitors of apoptosis 
proteins (cIAPs) are essential regulators of cell death 
and immunity. Nucleotide-binding oligomerization do-
main-like receptor type 1 (NLRX1) [308] binds to viral 
protein PB1-F2, preventing IAV-induced macrophage 
apoptosis and promoting both macrophage survival and 
type I IFN signaling. Interestingly, compounds that in-
hibit this enzymatic activity could be useful as anti-in-
fluenza antivirals. Indeed, Wurzer et al. have shown that 
apoptotic activation by caspase 3 is required for efficient 
virus production [306]. Furman and collaborators have 
demonstrated that the apoptotic index is a predictive bio-
marker of influenza vaccine responsiveness [309]. How-
ever, the question of whether apoptosis is beneficial to 
the viral reproductive cycle or to host cells is still under 
debate. Moreover, Hinshaw et al.  [307] demonstrated 
that, on inhibiting apoptosis during viral infection, influ-
enza virus RNP complexes were retained in the nucleus. 
Therefore, the use of caspase  3 inhibitors could have 
good potential as anti-influenza drugs [310].
Autophagy
Autophagy (or autophagocytosis) is a catabolic mecha-
nism that involves cellular breakdown of dysfunctional 
cell components through the involvement of lysosomes. 
Procyanidin has an anti-IAV activity [311].
Glucosidase, mannosidase and 
glycosilation inhibitors
L-fructose and L-xylulose can inhibit influenza virus 
replication  [312]. Glucosidase I and glucosidase II in-
hibitors include iminosugars, which alter glycan pro-
cessing of influenza HA and NA [313].
Pathway inhibitors
Raf/MEK/ERK pathway inhibitors include compounds, 
which act as an inhibitor of MEK1 and MEK2  [3]. 
NFKB inhibitors include Bortezomib [3], among others. 
These proteasome inhibitors are also effective against 
paramyxoviruses, HRV, poliovirus, coxsackievirus, 
HSV and HIV.
Phospholipase inhibitors
Lipid metabolism plays a fundamental role during in-
fluenza virus replication: membranes and their compo-
nents, such as sphingolipids, are crucial to all steps of 
the viral life cycle, from attachment and membrane fu-
sion, to intracellular transport, replication, protein sort-
ing and budding. Infection by influenza virus stimulates 
phospholipase D (PLD) activity [314].
Release inhibitors
HDAC6 is an anti-IAV host factor that negatively regu-
lates the trafficking of viral components to the host cell 
plasma membrane via its substrate, acetylated microtu-
bules [315].
As an anti-influenza chemical, cyclosporin A does not 
act through its classical targets, namely cyclophilin 
A (CypA), cyclophilin B (CypB) and P-glycoprotein 
(Pgp)  [316], but by inhibiting influenza virus release. 
Ching-fang-pai-tu-san (CFPTS) has a similar ac-
tion [317].
Anti-oxidants, anti-inflammatory 
compounds and immunomodulators
Oxidation plays a major role in influenza virus life cy-
cle and replication [318]. With regard to anti-influenza 
drugs that act subsequently to the various stages of vi-
ral replication, after the formation of vRNPs, it is worth 
considering that Resveratrol may be useful as an anti-
influenza drug. Indeed, this compound could interfere 
with the translocation of RNPs from the nucleus to the 
cytoplasm [319-321]. Dehydroascorbic acid also has an-
tiviral properties [322, 323].
Calcitriol prior to/or post-H1N1 exposure does not affect 
viral clearance but significantly reduces autophagy and 
restores the increased apoptosis seen on H1N1 infection 
to its constitutive level. However, it significantly reduces 
the levels of H1N1-induced TNF-α (tumor necrosis fac-
tor-alpha), RANTES, IL8, IFN-β (interferon-beta) and 
IFN-stimulated gene-15 (ISG15). 1,25[OH]2 D3 treat-
ment prior to/or post-H1N1 infection significantly down-
regulates both IL-8 and IL-6 RNA levels [324, 325].
Publications on antiviral drugs are often devoted to the 
use of statins as anti-flu drugs [326-328]. In particular, 
Fedson has suggested treating patients affected by H5N1 
with statins [326, 327]. Studies in vitro, in animals and 
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in the field seem to support this strategy. Statins are 
held to act through various mechanisms: through im-
munomodulatory and anti-inflammatory activity, by 
interfering with the proteins of the cytoskeleton and 
the interaction between these and the lipid rafts, and 
by reducing the availability of intracellular cholester-
ol. The balanced content of cholesterol in the cell is 
critical to the replication of IAV. Indeed, a reduction 
in cholesterol could impair the infectivity of progeny 
influenza viruses, probably by reducing the cholester-
ol content of the viral envelope [328]. However, some 
studies have found statins to be ineffective against in-
fluenza viruses [329, 330].
Extracts from Epimedium koreanum Nakai have immu-
nomodulatory properties [331], also against HSV, VSV 
and Newcastle Disease Virus (NDV). Carrageenan [332] 
extracted from edible red seaweeds can be administered 
as a nasal spray [333]. In particular, iota-carrageenan ap-
pears to be the most effective against influenza. 
Cycloferon  [334-336], amixin, Larifan, Kagocel and 
Ragosin stimulate B cells and macrophages to produce 
IFN-alpha [337]. They are widely used in Russia.
Apocynin, a NADPH oxidase type 2 (NOX2) inhibi-
tor, stimulates cell superoxide production. However, in 
certain conditions, it can also act as a ROS production 
stimulator in non-phagocyte cells  [338]. By contrast, 
NADPH oxidase type 1 (NOX1) has anti-inflammatory 
activity and inhibits ROS production [339, 340]. 
Rolipram, a selective phosphodiesterase-4 (PDE-4) in-
hibitor with antidepressant properties, and sertraline, a 
selective serotonin reuptake inhibitor (SSRI), exhibit 
strong antiviral activities if combined with oseltami-
vir  [341]. The rationale for using PDE-4 is that it be-
longs to a family of enzymes that metabolize cyclic 
adenosin monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP), which are commonly found 
during inflammatory and immune responses. By reduc-
ing bronchospasm and bronchoconstriction, it reduces 
mortality and morbidity in a mouse model. SSRI down-
regulates the expression of interferon-alpha, TNF-alpha, 
IL-6, IL-10 and T helper 1 (Th1) cells, and modulates 
immune responses from the Th1 toward the Th2 phe-
notype.
Sphingosine mimetics are able to finely modulate the re-
lease of cytokines and chemokines. In one study [342], 
neutralizing antibody and cytotoxic T cell responses 
were seen to be reduced, though still protective. As a 
result, the infiltration of PML and macrophages into the 
lung was markedly reduced, and thus also pulmonary 
tissue injury. DC maturation was suppressed, which lim-
ited the proliferation of specific antiviral T cells in the 
lung and draining lymph nodes. Furthermore, they were 
effective in controlling CD8(+) T cell accumulation in 
the lungs even when given 4 days after the onset of in-
fluenza virus infection.
Leucomycin A3 (LMA3), a macrolide antibiotic, inhib-
its neutrophil myeloperoxidase (MPO), which contrib-
utes to the pathogenesis and progression of severe influ-
enza-induced pneumonia, and mediates the production 
of hypochlorous acid, a potent tissue injury factor [343].
BG-777, derived from leukotriene B4, exerts both antivi-
ral and stimulatory activities on the host defence system. 
It is also active against HIV, RSV and Coronaviruses. It 
recruits leukocytes and fosters the release of chemokines 
such as MIP1-beta and defensins [344].
QS-21 is a molecule with immunomodulatory proper-
ties, and is currently being investigated as an adju-
vant for vaccines against influenza [345]. Thymalfasin 
(Zadaxin), which is derived from thymosin alpha-1, is 
another powerful adjuvant [346-348]. Canakinumab (Il-
aris), an IL1-beta blocking antibody, is also a promising 
compound in immunotherapy [349].
Some observations should be made on influenza therapy 
with non-steroidal anti-inflammatory drugs. Seasonal 
flu is normally treated with over-the-counter (OTC) 
drugs, which are designed to relieve symptoms. The 
most common are paracetamol, acetylsalicylic acid 
(which, however, is contraindicated in individuals un-
der 18 years of age) and ibuprofen or other NSAIDs. 
Coughing is usually mitigated by means of drugs that 
use dextromethorphan or acetylcistein as their active in-
gredient [350-357].
The inflammation driven by innate immunity is usu-
ally sufficient to cure the disease. However, especially 
when the virus is particularly virulent or during pandem-
ics, immunity may be dysregulated (cytokine-storm), 
which may give rise to very severe forms of influenza. 
The treatment of both seasonal and pandemic influenza 
therefore utilises appropriate and timely anti-inflamma-
tory therapy. Some of the above-mentioned drugs, such 
as statins and naproxen, have anti-inflammatory proper-
ties; however, they are probably also able to exert a real 
antiviral activity.
In the light of the human cases of infection by the H5N1 
strain and the lethal cases caused by the H1N1pdm vi-
rus, the need for modulators of innate immunity is of 
particular importance. Indeed, patients with severe or 
fatal human infections due to the H1N1pdm virus, for 
instance, have high pro-inflammatory responses early in 
the illness.
For the above-mentioned reasons, the literature often re-
ports in vitro and animals studies which demonstrate the 
therapeutic utility of anti-inflammatory and immune-
modulatory compounds, such as fibrates, against influ-
enza. 
Gene therapies
Gene therapy consists of modulating (up-regulating or 
down-regulating) genes and/or their products involved 
in the response to influenza [358]. 
microRNAs (miRNAs) are small non-coding RNA mol-
ecules (containing about 22 nucleotides) which function 
in RNA silencing or RNA interference (RNAi) and in 
the post-transcriptional regulation of gene expression. 
Host miRNAs are able to down-regulate the expression 
of viral genes. Therefore, miRNA modulation could be 
a promising approach in influenza treatment, despite 
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the difficulties of delivering miRNAs to cells efficient-
ly [359-363].
Small interfering RNAs (siRNAs) are also mediators of 
RNAi. They are short (19-26 nucleotides) and induce 
sequence-specific degradation of homologous mR-
NA [364-366].
Long non-coding RNAs (lncRNAs) modulate various 
biological processes [367]. One lncRNA, in particular, 
plays a major role; it acts as a negative regulator of anti-
viral response (NRAV) and is down-regulated during in-
fluenza infection. NRAV negatively regulates the tran-
scription of multiple critical interferon-stimulated genes 
(ISGs), by remodeling chromatin [368].
Compounds with unknown mechanisms
In the case of some compounds, the precise nature of 
their pharmacological activity against influenza is still 
unknown and requires further research.
Nanoparticles are a promising nanobiotechnological 
tool that can act as carriers of non-conjugated nanopar-
ticles. Silver nanoparticles  [369, 370] modulate SP-A 
and SP-D [371], and can be used to deliver RNAi [372]. 
Poly(gamma-glutamic) acid [373], fullerenes [374], chi-
tosan or N-trimethyl chitosan (TMC)  [375] and poly-
meric nanoparticles have also been investigated as vac-
cine adjuvants [376, 377]. However, single-walled car-
bon nanotubes (SWCNTs) seem to increase influenza 
virus pathogenicity and infectivity [378]. 
Combination therapies
Combination therapies (CTs) can be divided into as-
sociations of two or more drugs directly targeting viral 
components, and associations of a direct-acting viral 
compound and a molecule targeting host components. 
CTs may improve clinical outcomes, reduce the risk of 
respiratory complications, mortality and morbidity, re-
duce the risks of using single drugs (such as resistance, 
dose-related toxicity or other side-effects) and may po-
tentiate and enhance antiviral activity  [379, 380]. CTs 
can, in turn, be further divided into early combination 
chemotherapy (ECC) and sequential multidrug chemo-
therapy (SMC). Furthermore, many studies have evalu-
ated the efficacy of combining anti-inflammatory drugs 
with antiviral drugs in comparison with single-drug 
treatment. However, not all combination therapies, for 
instance the combination of oseltamivir with zanamivir 
or simvastatin with oseltamivir, are superior to mono-
therapy [102, 379, 380].
CTs can also exploit various chimeric monoclonal anti-
bodies [381].
Conclusions
In the last few decades, few antiviral molecules against 
influenza virus infections have been available. This 
has conditioned their use during human and animal 
outbreaks. Indeed, during seasonal and pandemic out-
breaks, antiviral drugs have usually been administered 
in mono-therapy and, sometimes, in an uncontrolled 
manner to farm animals. This has led to the emergence 
of viral strains displaying resistance, especially to com-
pounds of the amantadane family. For this reason, it is 
particularly important to develop new antiviral drugs 
against influenza viruses. Indeed, although vaccination 
is the most powerful means of mitigating the effects of 
influenza epidemics, antiviral drugs can be very useful, 
particularly in delaying the spread of new pandemic vi-
ruses, thereby enabling manufacturers to prepare large 
quantities of pandemic vaccine. In addition, antiviral 
drugs are particularly valuable in complicated cases of 
influenza, especially in hospitalized patients. This lat-
ter are individuals at risk, such as the elderly or patients 
with chronic respiratory diseases. For these subjects, it 
would be particularly important to have more antivirals 
to be administered in appropriate manner.
In the light of the extensive experience gained through 
the use of anti-influenza drugs, and in the light of the 
considerable advances in the search for new effective 
molecules against influenza viruses, many important 
considerations can be made. 
Firstly, the study of new compounds should be conduct-
ed in a more rational way. Indeed, the models and meth-
ods used by various scholars display marked differenc-
es. These studies often involve in vitro cell cultures and 
usually use Madin–Darby canine kidney (MDCK) cells 
and African green monkey kidney Vero cells. However, 
human tracheal epithelial cell cultures are sometimes 
used. While some authors have assessed the inhibition 
of viral growth by applying the haemagglutination test 
to the supernatant of the cell monolayer, others have 
used the inhibition of the virus-induced Cytopathic Ef-
fect (CPE). Furthermore, more sophisticated tests have 
been used – for instance, qPCR with the aim of amplify-
ing sequences of viral genes, such as the M2 gene, NP 
gene, etc., or RT-PCR with the aim of quantifying IAV 
RNA after in vitro antiviral treatment of cell cultures 
exposed to different influenza virus strains. In addition, 
the murine model is the most widely used to study influ-
enza compounds, as influenza causes fatal pneumonia in 
the mouse. Obviously, the human is the best, but results 
in humans are available only if clinical trials have been 
performed or if the drug has been licensed. However, as 
it is very costly to develop a new compound for com-
mercialization, preliminary evaluations in vitro and in 
animal models are very important. In some cases, it is 
also useful to carry out epidemiological studies on drugs 
used for other purposes, in order to investigate their pos-
sible therapeutic efficacy against influenza. 
To optimise the development of influenza antivirals, it 
is very important to define standardized methods for the 
evaluation of the molecules that have been hypothesized 
to have a potential antiviral effect. In in vitro studies, 
for instance, it is important to define the cell line that 
should be used (MDCK, or VERO, or THE cell line), the 
standard virus that should be tested (PR8 and/or High 
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pathogenic virus, such as H5N1) and the antiviral assay 
that should be performed (Haemagglutination, CPE in-
hibition, RT-PCR). Likewise, in in vivo tests, the choice 
of which animal to utilize should be established, while 
in human studies it is important to determine the number 
and age of the subjects to be studied. Only if standard-
ized methods are defined, will it be possible to correctly 
evaluate the antiviral potential of the compound under 
examination. In this perspective, it is also important to 
compare the antiviral activity of the hypothetical antivi-
ral with that of reference drugs (amantadine, oseltami-
vir, etc) in order to ascertain the influenza antiviral index 
of the new molecule. In in vitro studies, it is also advis-
able to evaluate the capacity of the antiviral under study 
to induce viral resistance.
In the field of medicinal chemistry, the discovery and 
development of a completely New Molecular Entity 
(NME) or compound is particularly expensive in terms 
of time and costs. Research could therefore be carried 
out along two different lines: designing/optimising new 
derivatives from an existing lead (such as the second-
generation NAI laninamivir and peramivir); and repur-
posing/repositioning existing drugs for new potential 
clinical applications  [382, 383]. The latter approach, 
also termed drug retasking or reprofiling, has already 
yielded promising results. While drug retargeting was 
initially serendipitous, it was later more systematically 
developed and exploited, not least by combining ad-
vanced biochemical, biophysical and bioinformatics/
cheminformatics techniques. Viroinformatics [384] and 
computational systems biology [385] can suggest ration-
al inhibitors of viral transcription, replication, protein 
synthesis, nuclear export and assembly/release. Other 
strategies may emerge from gene data mining. In this 
regard, Bao and collaborators used a prioritizing gene 
approach in order to find the most important genes in-
volved in host resistance to influenza virus [386]. They 
found that the response was controlled by two TNF-me-
diated pathways: apoptosis and TNF receptor-2 signal-
ing pathways. In addition, systems pharmacometrics and 
systems pharmacology  [387] could identify valuable 
CTs by studying drug synergy.
Secondly, the available anti-influenza drugs should be 
used in an appropriate manner, in order to impede or to 
mitigate the phenomenon of viral resistance. In this re-
gard, the first question is: what anti-inflammatory drug 
should be chosen? The answer should take into account 
the age of the patient, the toxicity and tolerability of the 
drug and its efficacy in alleviating the patient’s symp-
toms. Obviously, therapy should be initiated as soon as 
possible, and an NSAID (aspirin only for subjects over 
18 years, ibuprofen, naproxen or paracetamol [acetami-
nophen]) should be chosen. These compounds not only 
relieve the symptoms, but also equilibrate the patient’s 
innate immunity and sometimes have a direct or indirect 
antiviral effect. For instance, it is interesting that reduc-
ing pro-inflammatory cytokines diminishes the activity 
of proteases involved in HA cleavage. In addition, the 
administration of acetylcysteine is useful not only be-
cause of its mucolytic action, but also on account of its 
antioxidant activity.
The choice of the antiviral should take into account the 
broad resistance of influenza viruses to amantadane 
drugs and also the fact that mono-therapy can easily 
lead to the emergence of novel viral resistance. In this 
perspective, topic drugs, such as zanamivir, have proved 
to generate less resistant viral strains than drugs admin-
istered orally. In addition, other antivirals, such as anti-
protease drugs, could be useful in influenza therapy. 
These compounds could have advantages in that, being 
inhibitors of cellular proteins, they should be less prone 
to selecting resistant viral strains. However, it should be 
borne in mind that disturbing the cellular environment in 
order to disrupt viral functions could have adverse side 
effects. Furthermore, it has been proposed that therapeu-
tic protocols involving a combination of two or more 
antivirals should be drawn up in order to reduce the de-
velopment of drug-resistant viral strains and, at the same 
time, administer lower drug doses. Another hypothesis 
could be to administer two or more different antivirals 
alternately.
Finally, the use of antivirals in the veterinary field (for 
example, chicken flocks) should be carefully controlled, 
and in this case the combined or alternated administra-
tion of at least two antiviral drugs should be the rule. It 
is important to realise that this implies a one world, one 
health, one medicine, one science approach [382, 383], 
in which human and veterinary medicine cooperate in 
the interest of global health in an increasingly intercon-
nected world.
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